ANDA 202931, held by Pharmobedient. Frovatriptan Succinate.
As of Nov 16, 2026, ANDA 202931 (Frovatriptan Succinate), held by Pharmobedient, was first approved by FDA on Aug 28, 2014, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 28, 2014 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Frovatriptan SuccinateEQ 2.5MG BASE · tablet;oral | Frovatriptan Succinate | Discontinued |
| Oct 22, 2019 | Supplement 4Labeling · Standard review | Approved | None posted |
| Oct 22, 2019 | Supplement 1Labeling · Standard review | Approved | None posted |
| Aug 28, 2014 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters